Shkreli: Pharmaceutical company Pliva failed clinical trials for BPC-157
Martin Shkreli · The Great Peptide Debate with Martin Shkreli & Max Marchione · Mar 23, 2026 · at 13:21
Biotech entrepreneur Martin Shkreli argues against BPC-157 efficacy during a debate on therapeutic peptides with Max Marchione.
0:00 / 0:09exact quote · 9.3s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Pleva was a local drug company in the Balkans. Very well-respected, in my head. Pleva actually licensed BPC and tried to do clinical trials for it, and guess what? They failed!”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Martin Shkreli
Shkreli: BPC-157 is a scam with zero therapeutic value
“BPC-one-five-seven is the biggest scam I've ever seen. It does absolutely nothing. There's no redeemable value to this.”
Jane Street, Millennium, Citadel bid on Aschenbrenner's liquidated fund assets
“Interestingly, we heard that three firms were bidding on the assets. So Jane Street, Millennium and Citadel were sort of brought in in a closed Close circle sort of late Friday to bid on the remains of the firm.”
Shkreli: Aschenbrenner shopped Anthropic stake at $1.1T valuation for liquidity
“And the rumor is over the weekend, he contacted about 10 parties to place Anthropic in an effort to shore up liquidity, selling the Anthropic stake for allegedly the offer was at a 1.1 trillion equivalent market cap which, you know, I think roughly where it's …”
Shkreli: Peptide craze is driven by psychological issues and institutional distrust
“I'm very concerned about the peptide craze. I think it comes mostly out of psychological issues which we'll discuss. The need for identity, control distrust of institutions, all kinds of things like that are leading to what we're seeing today.”
Shkreli: No clinical trial of BPC-157 will ever work
“I would bet anything. I would bet anything. No trial of BPC would work.”
Shkreli: Mike Bloomberg could be worth $400B-$500B via private equity
“He's taken the Bloomberg dividends and pumped it into a family office that basically Carlisle and all these guys, you know, the Warburg Pincus, all the private equity guys like KKR, They go to him first, and he tosses in, like, five hundred million in each of …”